0000899243-20-019873.txt : 20200721
0000899243-20-019873.hdr.sgml : 20200721
20200721193910
ACCESSION NUMBER: 0000899243-20-019873
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200717
FILED AS OF DATE: 20200721
DATE AS OF CHANGE: 20200721
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goyal Vikas
CENTRAL INDEX KEY: 0001721017
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39381
FILM NUMBER: 201039945
MAIL ADDRESS:
STREET 1: C/O SR ONE, LTD., 161 WASHINGTON ST.
STREET 2: SUITE 500, EIGHT TOWER BRIDGE
CITY: CONSHOHOCKEN
STATE: PA
ZIP: 19428
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pandion Therapeutics, Inc.
CENTRAL INDEX KEY: 0001807901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 833015614
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 134 COOLIDGE AVENUE
STREET 2: 2ND FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-393-5925
MAIL ADDRESS:
STREET 1: 134 COOLIDGE AVENUE
STREET 2: 2ND FLOOR
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: Pandion Therapeutics Holdco LLC
DATE OF NAME CHANGE: 20200327
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-17
0
0001807901
Pandion Therapeutics, Inc.
PAND
0001721017
Goyal Vikas
C/O PANDION THERAPEUTICS, INC.,
134 COOLIDGE AVENUE
WATERTOWN
MA
02472
0
1
0
0
See Remarks
Common Stock
2020-07-21
4
C
0
7044
A
86314
D
Common Stock
2020-07-21
4
P
0
1450
18.00
A
87764
D
Stock Option (right to buy)
18.00
2020-07-17
4
A
0
3806
0.00
A
2030-07-16
Common Stock
3806
3806
D
Stock Option (right to buy)
18.00
2020-07-17
4
A
0
13935
0.00
A
2030-07-16
Common Stock
13935
13935
D
Stock Option (right to buy)
18.00
2020-07-17
4
A
0
10486
0.00
A
2030-07-16
Common Stock
10486
10486
D
Series B Preferred Stock
2020-07-21
4
C
0
35922
0.00
D
Common Stock
7044
0
D
The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on August 1, 2020, with the remainder of the shares vesting in equal monthly installments following August 1, 2020 through August 1, 2023, subject to the reporting person's continued service on each applicable vesting date.
This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date.
This option award was granted on June 25, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date.
Senior Vice President, Business Development
/s/ Edward Freedman, as attorney-in-fact for Vikas Goyal
2020-07-21